TP53 Mutational Status and Prediction of Benefit from Adjuvant 5-Fluorouracil in Stage III Colon Cancer Patients

We investigated the hypothesis that the varying treatment efficacy of adjuvant 5-fluorouracil (5FU) in stage III colon cancer is linked to the TP53 mutational status. ABCSG-90 was a prospective randomized trial in which effect of adjuvant 5FU was studied in stage III colon cancer patients. Tumor mat...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:EBioMedicine
Egile Nagusiak: Kandioler, Daniela, Mittlböck, Martina, Kappel, Sonja, Puhalla, Harald, Herbst, Friedrich, Langner, Cord, Wolf, Brigitte, Tschmelitsch, Jörg, Schippinger, Walter, Steger, Günther, Hofbauer, Friedrich, Samonigg, Hellmut, Gnant, Michael, Teleky, Bela, Kührer, Irene
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Elsevier 2015
Gaiak:
Original Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4563117/
https://ncbi.nlm.nih.gov/pubmed/26425688
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ebiom.2015.06.003
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak